Form 4: Disc Medicine CEO Executes Pre-Arranged Option Exercise and Share Sale

Disc Medicine, Inc.'s CEO and Director, John D. Quisel, completed a pre-scheduled exercise of stock options and subsequent sale of common shares on July 3, 2025, under a Rule 10b5-1 trading plan.

Summary

• John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc. (IRON), engaged in transactions on July 3, 2025.
• Exercised stock options to acquire 5,200 shares of common stock at an exercise price of $9.86 per share.
• Immediately after the exercise, sold 5,200 shares of common stock at a weighted average price of $55.0874 per share.
• The sales occurred in multiple transactions with prices ranging from $55.00 to $55.26.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, John D. Quisel beneficially owns 161,828 shares of common stock and 150,175 stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While it's an insider sale, it's under a 10b5-1 plan, which mitigates negative sentiment. The significant difference between exercise and sale price indicates the executive is realizing gains from previously granted compensation, which is a normal part of executive compensation.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating a pre-planned sale rather than a discretionary trade based on new, non-public information.
• The sale price of $55.0874 per share is significantly higher than the exercise price of $9.86 per share, indicating a substantial gain for the insider on the exercised options.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity exposure.

Future Outlook

This document, an SEC Form 4, details insider transactions and does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing reports an individual insider transaction, which is specific to Disc Medicine, Inc. and its executive's compensation and liquidity management. It does not provide information relevant to broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative, though mitigated by the 10b5-1 plan. The sale at a significantly higher price than the exercise price indicates the executive is realizing value from their equity compensation.

Key Dates

Recommendation

Keywords

Disc Medicine, IRON, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, John D. Quisel, CEO, Director, Beneficial Ownership